Mirabegrón Teva (Mirabegron)

Mirabegron, the active ingredient in Mirabegrón Teva, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients. GNH USA supplies Mirabegrón Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegrón is indicated for conditions affecting bladder storage function within the overactive bladder disease family. - Overactive bladder: increases bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases daytime voiding frequency.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dry mouth - Constipation - Hypertension - Headache - Nasopharyngitis - Urinary retention (mild)

Serious or Rare Side Effects: - Severe urinary retention requiring catheterisation - Hypertensive crisis - Tachycardia - Angioedema - Anaphylactic reaction - Acute renal impairment

Before initiating therapy, consider patient‑specific risk factors and monitoring requirements. - Cardiovascular assessment: monitor blood pressure regularly. - Renal function evaluation: adjust use in severe impairment. - Concomitant medication review: avoid strong CYP2D6 inhibitors. - Caution in uncontrolled hypertension: assess risk‑benefit. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirabegrón may interact with several drug classes; clinical judgement is required.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Anticholinergic agents: combined use can heighten risk of urinary retention. - Other β3‑adrenergic agonists: additive pharmacologic effect may increase adverse events.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Diuretics: concurrent use may exacerbate hypertension. - NSAIDs: may potentiate blood‑pressure elevation. - Digoxin: potential alteration of serum concentrations.